Abstract
Noise-modulating chemicals can synergize with transcriptional activators in reactivating latent HIV to eliminate latent HIV reservoirs. To understand the underlying biomolecular mechanism, we investigate a previous two-gene-state model and identify two necessary conditions for the synergy: an assumption of inhibition effect of transcription activators on noise enhancers; and frequent transitions to the gene non-transcription-permissive state. We then develop a loop-four-gene-state model with Tat transcription/translation and find that drug synergy is mainly determined by the magnitude and direction of energy input into the genetic regulatory kinetics of the HIV promoter. The inhibition effect of transcription activators is actually a phenomenon of energy dissipation in the nonequilibrium gene transition system. Overall, the loop-four-state model demonstrates that energy dissipation plays a crucial role in HIV latency reactivation, which might be useful for improving drug effects and identifying other synergies on lentivirus latency reactivation.
Introduction
The primary obstacle to a clinical cure for HIV is "proviral latency"—a state where the virus integrates into the host genome but remains dormant. In this state, the virus is invisible to both the immune system and standard antiretroviral therapies (ART). The "shock and kill" strategy aims to overcome this by reactivating (shocking) these latent reservoirs so they can be eliminated (killed) by the immune system or targeted therapies.
Recent experimental breakthroughs have identified a promising synergistic approach: combining Activators (AC), which increase the mean level of gene expression, with Noise Enhancers (NE), which increase the fluctuations or "flicker" in expression. While this combination (1+1 > 2) has shown success in the lab, the underlying physical and mathematical mechanisms have remained poorly understood. Standard biological models often require forced, ad-hoc assumptions to replicate this synergy. This research investigates the fundamental nonequilibrium physics that drive this interaction.
Modeling the HIV Promoter
To uncover the mechanism of synergy, the researchers explored two mathematical frameworks using the Stochastic Simulation Algorithm (SSA):
The LTR-2-State Model
The study began with a standard two-state model where the HIV promoter (LTR) toggles between an "on" (transcriptionally active) and "off" (inactive) state. They found that this model only predicts synergy if one assumes that the activator directly inhibits the noise enhancer. However, such a specific biochemical interference is not always supported by experimental evidence, suggesting the 2-state model is an incomplete representation of the system.
The Loop-LTR-4-State Model
To find a more robust explanation, the authors developed a four-state model. This model represents various binding states of the promoter, accounting for the presence or absence of RNA polymerase and activators. Crucially, this model allows for a "loop" in the transition network. By comparing a version of the model in thermodynamic equilibrium (detailed balance) against a nonequilibrium version (non-detailed balance), the researchers could isolate the role of energy.
The Role of Nonequilibrium Energy Dissipation
The study’s most significant finding is that drug synergy is a product of nonequilibrium dynamics. In a system at thermodynamic equilibrium, the noise enhancer would slow down all transitions equally, effectively canceling out any synergistic benefit from the activator. Synergy is mathematically impossible in such a state.
In the nonequilibrium model, energy input (denoted as $\beta$, representing processes like ATP hydrolysis) drives a directional "cycle flux" around the four-state loop. The researchers found that:
- Directionality Matters: Synergy only occurs when energy input drives a clockwise cycle flux. This specific direction ensures that once an activator kicks the gene into an "on" state, the noise enhancer acts to "trap" the promoter in that active state for a longer duration.
- Energy as a Driver: The magnitude of energy dissipation directly correlates with the strength of the synergy. This suggests that the "inhibition effect" observed in simpler models is actually a manifestation of energy dissipation within the complex gene transition system.
Key Results and Implications
Using kinetic parameters derived from established HIV literature, the nonequilibrium model successfully replicated experimental benchmarks:
- Reactivation Efficiency: In the optimized model, an activator alone reactivated approximately 7% of latent cells. When combined with a noise enhancer, reactivation jumped to 13%, matching the high-performance scenarios observed in laboratory settings.
- Universality: The model explains why synergy is observed across a diverse range of noise enhancers. Rather than requiring specific molecular "handshakes" between different drugs, the synergy is a generic result of how energy flows through the genetic regulatory circuit of the HIV promoter.
- Robustness: These findings held true even when accounting for realistic cellular factors like protein partitioning during cell division.
Conclusion
This research shifts the focus of HIV reactivation from purely biochemical interactions to the underlying energetics of gene regulation. By demonstrating that energy dissipation is the primary driver of drug synergy, the study provides a new framework for optimizing "shock and kill" therapies. Future work may involve tuning phosphorylation energy in T-cells to validate these predictions experimentally and applying this nonequilibrium framework to other biological systems, such as cancer cell transitions or other latent viruses.
Summary updated